Creekmur Asset Management LLC Invests $291,000 in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Creekmur Asset Management LLC purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 40,946 shares of the company's stock, valued at approximately $291,000.

A number of other institutional investors have also recently added to or reduced their stakes in NTLA. California State Teachers Retirement System boosted its stake in Intellia Therapeutics by 4.1% during the fourth quarter. California State Teachers Retirement System now owns 90,638 shares of the company's stock worth $1,057,000 after acquiring an additional 3,596 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Intellia Therapeutics in the 4th quarter worth $4,793,000. Baker BROS. Advisors LP bought a new stake in Intellia Therapeutics during the 4th quarter valued at $7,510,000. XTX Topco Ltd increased its stake in Intellia Therapeutics by 194.6% during the 4th quarter. XTX Topco Ltd now owns 43,908 shares of the company's stock valued at $512,000 after purchasing an additional 29,006 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Intellia Therapeutics by 12.1% in the fourth quarter. Deutsche Bank AG now owns 252,501 shares of the company's stock valued at $2,944,000 after buying an additional 27,282 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NTLA shares. Wedbush restated a "neutral" rating and set a $7.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Intellia Therapeutics in a report on Monday, June 16th. Canaccord Genuity Group decreased their price objective on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research note on Tuesday, June 3rd. Chardan Capital reissued a "buy" rating and set a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. Finally, Guggenheim cut their target price on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $33.37.

Intellia Therapeutics Stock Up 6.8%

Shares of NASDAQ NTLA traded up $0.86 during trading on Tuesday, reaching $13.49. The company had a trading volume of 5,619,415 shares, compared to its average volume of 3,108,756. The business's 50-day moving average is $9.54 and its 200 day moving average is $9.33. The stock has a market cap of $1.40 billion, a PE ratio of -2.58 and a beta of 2.21. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $27.42.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. Intellia Therapeutics had a negative return on equity of 56.06% and a negative net margin of 1,154.10%. Intellia Therapeutics's revenue was down 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.12) EPS. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.